Muscle MRI in Duchenne Muscular Dystrophy

Muscle MRI in Duchenne muscular dystrophy is the imaging examination of skeletal muscles, distinct from cardiac MRI, used to track how the disease progresses inside the muscles that move the arms and legs. It includes qualitative grading of fat infiltration (the Mercuri scale), quantitative measurements such as fat fraction and T2 relaxation time, and increasingly sophisticated techniques that capture inflammation and structural change. The findings complement functional tests like the 6-minute walk and the NSAA, often detecting changes before scores shift on the timed tests.

This post is a practical overview. The actual decision to order muscle MRI and how to use it belongs to the neuromuscular team.

Why image the muscles directly

Functional tests measure what a patient can do today. Muscle MRI shows what is happening inside the muscle itself, which can change measurably while function still looks stable. That earlier window is increasingly useful for clinical trials, where structural endpoints can demonstrate biological effect even when functional change is too small to detect, and it has growing use in routine care for tracking trajectory in selected patients.

For background on the functional measures it complements, see functional assessments in DMD.

What muscle MRI shows in DMD

Two findings dominate the picture:

• Fat infiltration, the gradual replacement of muscle fibres with fat as the disease progresses. This is visible on T1-weighted images and can be graded semi-quantitatively (Mercuri scale, 0 to 4) or measured precisely as fat fraction using Dixon-based MRI techniques. (Skeletal muscle MRI in DMD, PMC)
• Tissue inflammation and oedema, captured by T2 mapping. Elevated T2 values appear earlier in the disease than fat infiltration and reflect the inflammatory and degenerative-regenerative processes that precede fatty replacement.

The pattern in DMD is recognisable: certain muscles in the thigh and pelvis (vastus lateralis, biceps femoris, glutei) tend to be affected earlier than others, producing a characteristic distribution that experienced readers can identify.

Fat fraction and T2 as biomarkers

Two specific measurements have become important biomarkers for DMD research and selected clinical follow-up:

• Fat fraction (FF) quantifies the proportion of muscle replaced by fat, on a scale from 0 to 1.
• T2 mapping quantifies tissue water and reflects oedema, inflammation, and early degeneration.

Both correlate with functional measures and with age. Specifically, MRS fat fraction of the vastus lateralis and soleus and T2 MRI of the vastus lateralis and biceps femoris long head have been shown to predict loss of ambulation over 12 months in DMD cohorts. (Quantitative muscle MRI biomarkers in DMD, PMC)

Studies have estimated the minimal clinically important difference for fat fraction at around 0.01 to 0.05, and for T2 at around 0.8 to 3.7 milliseconds, providing a basis for interpreting change over time. (Clinical importance of changes in magnetic resonance biomarkers for DMD, PMC)

How muscle MRI is used today

The role of muscle MRI in DMD varies by setting:

• Clinical trials. Muscle MRI is now a frequent secondary endpoint in DMD therapeutic trials, providing structural evidence of biological effect that can support functional findings. A 2022 trial of domagrozumab used quantitative MRI as a biomarker of disease progression. (Quantitative MRI biomarkers in a Phase 2 DMD trial of domagrozumab, Springer)
• Selected clinical care. Some centres use muscle MRI to track trajectory in stable patients, identify early changes, or guide functional therapy. Routine use varies internationally.
• Diagnosis support. In atypical presentations, muscle MRI patterns can support a clinical diagnosis pending genetic confirmation.

For background on diagnosis, see the DMD diagnosis pathway.

What the scan is like

Practical points for families:

• The patient lies in the MRI scanner for 30 to 60 minutes, depending on the protocol.
• Most muscle MRI in DMD does not require contrast (gadolinium), which is different from cardiac MRI where contrast is often part of the protocol.
• Younger children may need sedation or general anesthesia to stay still; in DMD this is planned with the same precautions used for any other anesthesia procedure.
• The scanner is loud; ear protection is provided.
• Lower-extremity muscle protocols are most common, but arm and trunk protocols are increasingly used as the disease progresses beyond ambulation.

For background on anesthesia considerations, see anesthesia safety in DMD.

Limits and considerations

A few practical points:

• Muscle MRI is more expensive and less widely available than functional testing, and not all centres have neuromuscular-experienced readers. The value depends on the quality of the protocol and the reader.
• Quantitative measurements (fat fraction, T2 mapping) require specific sequences that may not be standard at all hospitals. Asking ahead whether the centre runs a quantitative DMD protocol is reasonable.
• For families travelling to a different centre for the scan, results should be interpreted alongside in-centre measurements, since absolute values can vary between scanners.
• Muscle MRI complements functional and cardiac assessment; it does not replace either.

For background on cardiac imaging, see cardiac MRI in DMD.

What families can ask

A short list at clinic visits:

• Does the centre offer muscle MRI as part of standard surveillance, or only when specifically indicated?
• Is a quantitative protocol (fat fraction, T2 mapping) used, or only the standard qualitative grading?
• How does the team integrate MRI findings with functional measures and treatment decisions?
• Is muscle MRI being used to support eligibility for any clinical trial?

What is still uncertain

Optimal intervals for routine muscle MRI in stable patients, the relationship between specific imaging changes and response to disease-modifying therapies, and the integration of newer techniques (diffusion, advanced strain analysis, fat-water separation) into clinical workflow continue to evolve.

The reasonable framing is that muscle MRI in DMD is a high-resolution biomarker that complements functional testing and is increasingly part of trial-grade and selected clinical care. The decisions about its use belong to the neuromuscular team.

For related reading, see functional assessments in DMD, cardiac MRI in DMD, the DMD research pipeline, and DMD standards of care.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.